{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:02:50Z","timestamp":1790762570988,"version":"4.1.0"},"reference-count":38,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmaceutical Statistics"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>The primary goal of Phase I\/II combination trials is to identify the optimal biological dose combination (OBDC), defined as the dose combination that achieves the highest efficacy while maintaining an acceptable toxicity rate. Several designs have been proposed for such trials. Among them, the local continual reassessment method for Phase I\/II trials (LOCRM12) performs well when compared with other model\u2010based methods in most of the scenarios studied. However, LOCRM12 assumes that both toxicity and efficacy outcomes are fully observed before enrolling the next cohort, an assumption that may not hold in real\u2010world settings, where late\u2010onset outcomes are increasingly common with the emergence of novel therapies such as molecularly targeted agents and immunotherapies. To address this limitation, we propose a time\u2010to\u2010event extension of LOCRM12 (TITE\u2010LOCRM12) that accommodates both late\u2010onset toxicity and efficacy outcomes. The local modeling framework, which uses data from neighboring dose combinations, is robust and efficient when data are sparse in complex combination settings. Simulation studies show that the proposed design can achieve a high percentage of correctly selecting the OBDC while maintaining a feasible trial duration.<\/jats:p>","DOI":"10.1002\/pst.70120","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:33:02Z","timestamp":1790760782000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["<scp>TITE<\/scp>\n                    \u2010\n                    <scp>LOCRM12<\/scp>\n                    : A Local Continual Reassessment Method for Drug Combination Optimization Based on Late\u2010Onset Toxicity and Efficacy Outcomes"],"prefix":"10.1002","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5536-3850","authenticated-orcid":false,"given":"Li","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Biostatistics Virginia Commonwealth University  Richmond Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2244-131X","authenticated-orcid":false,"given":"Ruitao","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Biostatistics The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nolan A.","family":"Wages","sequence":"additional","affiliation":[{"name":"Department of Biostatistics Virginia Commonwealth University  Richmond Virginia USA"},{"name":"Massey Comprehensive Cancer Center  Richmond Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"issue":"16","key":"e_1_2_9_2_1","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMp2109826","article-title":"The Drug\u2010Dosing Conundrum in Oncology\u2014When Less Is More","volume":"385","author":"Shah M.","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"e_1_2_9_3_1","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1158\/1078-0432.CCR-15-1295","article-title":"Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example","volume":"22","author":"Sachs J. R.","year":"2016","journal-title":"Clinical Cancer Research"},{"issue":"3","key":"e_1_2_9_4_1","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/j.0006-341X.2004.00218.x","article-title":"Dose\u2010Finding Based on Efficacy\u2013Toxicity Trade\u2010Offs","volume":"60","author":"Thall P. F.","year":"2004","journal-title":"Biometrics"},{"key":"e_1_2_9_5_1","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1200\/PO.20.00257","article-title":"BOIN12: Bayesian Optimal Interval Phase I\/II Trial Design for Utility\u2010Based Dose Finding in Immunotherapy and Targeted Therapies","volume":"4","author":"Lin R.","year":"2020","journal-title":"JCO Precision Oncology"},{"issue":"28","key":"e_1_2_9_6_1","doi-asserted-by":"crossref","first-page":"S5299","DOI":"10.1002\/sim.8361","article-title":"A Utility\u2010Based Bayesian Optimal Interval (U\u2010BOIN) Phase I\/II Design to Identify the Optimal Biological Dose for Targeted and Immune Therapies","volume":"38","author":"Zhou Y.","year":"2019","journal-title":"Statistics in Medicine"},{"issue":"1","key":"e_1_2_9_7_1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/sim.7082","article-title":"A Robust Two\u2010Stage Design Identifying the Optimal Biological Dose for Phase I\/II Clinical Trials","volume":"36","author":"Zang Y.","year":"2017","journal-title":"Statistics in Medicine"},{"issue":"523","key":"e_1_2_9_8_1","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1080\/01621459.2017.1383260","article-title":"A Bayesian Phase I\/II Trial Design for Immunotherapy","volume":"113","author":"Liu S.","year":"2018","journal-title":"Journal of the American Statistical Association"},{"issue":"10351","key":"e_1_2_9_9_1","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S0140-6736(22)01390-3","article-title":"Early Drug Development in Solid Tumours: Analysis of National Cancer Institute\u2010Sponsored Phase 1 Trials","volume":"400","author":"Chihara D.","year":"2022","journal-title":"Lancet"},{"issue":"12","key":"e_1_2_9_10_1","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1002\/sim.6097","article-title":"Phase I\/II Adaptive Design for Drug Combination Oncology Trials","volume":"33","author":"Wages N. A.","year":"2014","journal-title":"Statistics in Medicine"},{"issue":"1","key":"e_1_2_9_11_1","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/rssc.12039","article-title":"A Bayesian Dose Finding Design for Oncology Clinical Trials of Combinational Biological Agents","volume":"63","author":"Cai C.","year":"2014","journal-title":"Journal of the Royal Statistical Society. Series C, Applied Statistics"},{"issue":"2","key":"e_1_2_9_12_1","first-page":"924","article-title":"Bayesian Phase I\/II Adaptively Randomized Oncology Trials With Combined Drugs","volume":"5","author":"Yuan Y.","year":"2011","journal-title":"Annals of Applied Statistics"},{"issue":"11","key":"e_1_2_9_13_1","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1002\/sim.2707","article-title":"An Adaptive Phase I Design for Identifying a Biologically Optimal Dose for Dual Agent Drug Combinations","volume":"26","author":"Mandrekar S. J.","year":"2007","journal-title":"Statistics in Medicine"},{"issue":"5","key":"e_1_2_9_14_1","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/sim.6376","article-title":"Bayesian Dose\u2010Finding Designs for Combination of Molecularly Targeted Agents Assuming Partial Stochastic Ordering","volume":"34","author":"Guo B.","year":"2015","journal-title":"Statistics in Medicine"},{"issue":"4","key":"e_1_2_9_15_1","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1177\/09622802241236936","article-title":"BOIN\u2010ETC: A Bayesian Optimal Interval Design Considering Efficacy and Toxicity to Identify the Optimal Dose Combinations","volume":"33","author":"Kakizume T.","year":"2024","journal-title":"Statistical Methods in Medical Research"},{"issue":"10","key":"e_1_2_9_16_1","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1177\/09622802231192955","article-title":"Local Continual Reassessment Methods for Dose Finding and Optimization in Drug\u2010Combination Trials","volume":"32","author":"Zhang J.","year":"2023","journal-title":"Statistical Methods in Medical Research"},{"issue":"6","key":"e_1_2_9_17_1","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/pst.1895","article-title":"A Bayesian Hierarchal Modeling Approach to Shortening Phase I\/II Trials of Anticancer Drug Combinations","volume":"17","author":"Yada S.","year":"2018","journal-title":"Pharmaceutical Statistics"},{"issue":"1","key":"e_1_2_9_18_1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/19466315.2024.2333388","article-title":"Joint TITE\u2010CRM: A Design for Dose Finding Studies for Therapies With Late\u2010Onset Safety and Activity Outcomes","volume":"17","author":"Barnett H.","year":"2025","journal-title":"Statistics in Biopharmaceutical Research"},{"issue":"4","key":"e_1_2_9_19_1","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/j.0006-341X.2000.01177.x","article-title":"Sequential Designs for Phase I Clinical Trials With Late\u2010Onset Toxicities","volume":"56","author":"Cheung Y. K.","year":"2000","journal-title":"Biometrics"},{"issue":"2","key":"e_1_2_9_20_1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/biostatistics\/kxv040","article-title":"A Robust Bayesian Dose\u2010Finding Design for Phase I\/II Clinical Trials","volume":"17","author":"Liu S.","year":"2016","journal-title":"Biostatistics"},{"issue":"5","key":"e_1_2_9_21_1","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/j.1467-9876.2009.00674.x","article-title":"Bayesian Dose Finding by Jointly Modelling Toxicity and Efficacy as Time\u2010To\u2010Event Outcomes","volume":"58","author":"Yuan Y.","year":"2009","journal-title":"Journal of the Royal Statistical Society. Series C, Applied Statistics"},{"issue":"11","key":"e_1_2_9_22_1","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/sim.9337","article-title":"TITE\u2010BOIN12: A Bayesian Phase I\/II Trial Design to Find the Optimal Biological Dose With Late\u2010Onset Toxicity and Efficacy","volume":"41","author":"Zhou Y.","year":"2022","journal-title":"Statistics in Medicine"},{"issue":"506","key":"e_1_2_9_23_1","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/01621459.2014.881740","article-title":"Using Data Augmentation to Facilitate Conduct of Phase I\u2013II Clinical Trials With Delayed Outcomes","volume":"109","author":"Jin I. H.","year":"2014","journal-title":"Journal of the American Statistical Association"},{"issue":"4","key":"e_1_2_9_24_1","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/10543406.2019.1634087","article-title":"Generalization of the Time\u2010To\u2010Event Continual Reassessment Method to Bivariate Outcomes","volume":"29","author":"Yan D.","year":"2019","journal-title":"Journal of Biopharmaceutical Statistics"},{"key":"e_1_2_9_25_1","unstructured":"H.Barnett O.Boix D.Kontos andT.Jaki \u201cJoint TITE\u2010CRM for Dual Agent Dose Finding Studies \u201dpreprint arXiv 2025 arXiv:2502.05072."},{"issue":"4","key":"e_1_2_9_26_1","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1111\/j.1541-0420.2011.01560.x","article-title":"Continual Reassessment Method for Partial Ordering","volume":"67","author":"Wages N. A.","year":"2011","journal-title":"Biometrics"},{"key":"e_1_2_9_27_1","first-page":"95","volume-title":"Statistical Methods in Drug Combination Studies","author":"Neuenschwander B.","year":"2015"},{"issue":"2","key":"e_1_2_9_28_1","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1080\/19466315.2024.2370403","article-title":"Comb\u2010BOIN12: A Utility\u2010Based Bayesian Optimal Interval Design for Dose Optimization in Cancer Drug\u2010Combination Trials","volume":"17","author":"Lu M.","year":"2025","journal-title":"Statistics in Biopharmaceutical Research"},{"issue":"13","key":"e_1_2_9_29_1","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1158\/1078-0432.CCR-24-3669","article-title":"Practical Considerations for Using the TITE\u2010BOIN Design to Handle Late\u2010Onset Toxicity or Fast Accrual in Phase I Trials","volume":"31","author":"Chen K.","year":"2025","journal-title":"Clinical Cancer Research"},{"issue":"3","key":"e_1_2_9_30_1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/1740774509105076","article-title":"Model Calibration in the Continual Reassessment Method","volume":"6","author":"Lee S. M.","year":"2009","journal-title":"Clinical Trials"},{"key":"e_1_2_9_31_1","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2307\/2532905","article-title":"Continual Reassessment Method: A Likelihood Approach","volume":"52","author":"O'Quigley J.","year":"1996","journal-title":"Biometrics"},{"issue":"487","key":"e_1_2_9_32_1","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1198\/jasa.2009.ap08425","article-title":"Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials","volume":"104","author":"Yin G.","year":"2009","journal-title":"Journal of the American Statistical Association"},{"issue":"17","key":"e_1_2_9_33_1","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1002\/sim.4139","article-title":"Calibration of Prior Variance in the Bayesian Continual Reassessment Method","volume":"30","author":"Lee S. M.","year":"2011","journal-title":"Statistics in Medicine"},{"key":"e_1_2_9_34_1","first-page":"227","volume-title":"Applied Bayesian Modeling and Causal Inference From Incomplete\u2010Data Perspectives: An Essential Journey With Donald Rubin's Statistical Family","author":"Liu C.","year":"2004"},{"issue":"2","key":"e_1_2_9_35_1","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1177\/0962280216631763","article-title":"Phase I\/II Dose\u2010Finding Design for Molecularly Targeted Agent: Plateau Determination Using Adaptive Randomization","volume":"27","author":"Riviere M. K.","year":"2018","journal-title":"Statistical Methods in Medical Research"},{"key":"e_1_2_9_36_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2021.106605","article-title":"Controlled Backfill in Oncology Dose\u2010Finding Trials","volume":"111","author":"Dehbi H. M.","year":"2021","journal-title":"Contemporary Clinical Trials"},{"key":"e_1_2_9_37_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2022.107021","article-title":"Controlled Amplification in Oncology Dose\u2010Finding Trials","volume":"125","author":"Dehbi H. M.","year":"2023","journal-title":"Contemporary Clinical Trials"},{"issue":"7","key":"e_1_2_9_38_1","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41416-021-01412-y","article-title":"Randomised Phase 1 Clinical Trials in Oncology","volume":"125","author":"Iasonos A.","year":"2021","journal-title":"British Journal of Cancer"},{"issue":"3","key":"e_1_2_9_39_1","doi-asserted-by":"crossref","first-page":"352","DOI":"10.2307\/2347723","article-title":"Algorithm AS 206: Isotonic Regression in Two Independent Variables","volume":"33","author":"Bril G.","year":"1984","journal-title":"Applied Statistics"}],"container-title":["Pharmaceutical Statistics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pst.70120","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pst.70120","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pst.70120","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:33:08Z","timestamp":1790760788000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pst.70120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10.1002\/pst.70120"],"URL":"https:\/\/doi.org\/10.1002\/pst.70120","archive":["Portico"],"relation":{},"ISSN":["1539-1604","1539-1612"],"issn-type":[{"value":"1539-1604","type":"print"},{"value":"1539-1612","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"2025-11-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70120"}}